Dr. Jess Logan Rush, M.D. Dermatology - MOHS-Micrographic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4331 Highway 39 N Ste A, Meridian, MS 39301 Phone: 601-693-1044 |
Dr. Larry E Millikan, MD FAAD Dermatology - Procedural Dermatology Medicare: Not Enrolled in Medicare Practice Location: 2321 13th St, Meridian, MS 39301 Phone: 601-484-9490 Fax: 601-486-2457 |
Dr. Kenneth Daniel Saul, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5002 Highway 39 N Bldg A, Meridian, MS 39301 Phone: 601-512-0500 Fax: 601-512-0505 |
Anna Allred Wile, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4331 Highway 39 N Ste A, Meridian, MS 39301 Phone: 601-693-1044 |
Dr. Neill C Porter, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 4612 29th Ave, Meridian, MS 39305 Phone: 601-485-8535 |
Lawrence Benjamin Mceachin, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3827 Grandview Ave, Meridian, MS 39305 Phone: 601-485-9875 |
News Archive
The National Institute for Occupational Safety and Health has awarded U of U Health funding to establish a new Utah-based Center of Excellence for Total Worker Health as part of its national initiative to improve workplace wellness and safety through innovative collaborative work.
Haber, Inc. ("Haber"), (OTC: HABE), a Delaware corporation headquartered in Arlington, Mass., with proprietary technologies in the separations sciences and environmentally friendly processing of gold bearing ores, announced today that it has formed a wholly owned subsidiary incorporated in Delaware called "EMP Diagnostics Inc." ("EDI"). The business of the new company will focus on the application of Haber's Electromolecular Propulsion technology (EMP). EMP is a separation technology that achieves unrivaled molecular separation speeds and has other unique capabilities not attainable with electrophoresis or liquid chromatography.
From cutting-edge research and clinical trials focused on cancer care to creating a new center devoted to protecting personal data privacy, University of California, Irvine scholars, scientists and physicians are blazing new paths to help change the world.
Researchers in Europe have found no evidence to support previous reports that the use of drugs that target the renin-angiotensin-aldosterone system (RAAS) increases susceptibility to coronavirus disease 2019 (COVID-19). The research is published in the European Heart Journal.
› Verified 6 days ago